Advertisement

Topics

Dabrafenib and/or Trametinib Rollover Study

2017-11-20 03:45:11 | BioPortfolio

Published on BioPortfolio: 2017-11-20T03:45:11-0500

Clinical Trials [1039 Associated Clinical Trials listed on BioPortfolio]

Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown...

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabra...

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

The purpose of this study is to determine the maximum tolerated dose and the safety profile of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in subjects w...

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-...

Study for the Evaluation Dabrafenib (Tafinlar) and Trametinib (Mekinist) Plus DNE3 in Patients With Metastatic Melanoma

Previous studies have shown that combination of a BRAF inhibitor (dabrafenib) with MEK inhibitor (trametinib) and exhibit synergistic effects on tumor cells (melanoma), together with Akt i...

PubMed Articles [866 Associated PubMed Articles listed on BioPortfolio]

Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.

About 40 - 50% of cutaneous melanomas have activating BRAF mutations that are reachable with targeted therapy and combined BRAF-MEK inhibition improves clinical outcomes in advanced BRAF V600E/K-mutan...

Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.

BRAF and MEK inhibitors (BRAF/MEKi) are targeted therapy for proto-oncogene BRAF mutated metastatic unresectable melanoma. Compared to monotherapy, an increased cardiovascular toxicity is reported wit...

Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib.

Beating tumour drug resistance: "Lamarckian" induction in the spotlight.

Drug resistance is a major problem in cancer treatment. In cutaneous melanoma, a large fraction of tumours carry BRAF or BRAF mutations (hereinafter referred to as BRAF ), which result in activation o...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

More From BioPortfolio on "Dabrafenib and/or Trametinib Rollover Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial